Significantly, our study found that CLF is particularly effective against these putative myeloma stem-cell-like subclones with treatment-refractory phenotypes, including quiescent cells/dormant cells, ALDH+ cells, and SPs. The gene discussed is LDHA; the disease is plasma cell myeloma.